Gilead Sciences stock (US3755581036): Insider share sale follows new Livdelzi data

Gilead Sciences shares on Nasdaq remain in focus after CEO Daniel O'Day disclosed a pre-planned sale of 15,000 shares just days after the company reported new Phase 3 data for liver drug Livdelzi in primary biliary cholangitis.

Gilead Sciences is drawing investor attention in the United States after Chairman and CEO Daniel O'Day disclosed the sale of 15,000 company shares shortly after fresh clinical data for liver disease candidate Livdelzi was released.

According to a Form 4 filed with the U.S. Securities and Exchange Commission, O'Day executed three open-market sales totaling 15,000 Gilead Sciences shares on 06/01/2026 at prices around USD 131 per share, for aggregate proceeds of about USD 1.97 million, under a Rule 10b5-1 trading plan adopted on 02/25/2026, as reported by filings summarized by StockTitan and GuruFocus.

The disclosure comes as the U.S.-listed stock on Nasdaq (ticker: GILD) continues to trade actively; recent pricing data from MarketScreener show a last close near USD 127.57, with the company remaining a significant constituent of the U.S. large-cap biopharmaceutical universe.

The stock traded at around USD 127.57 on 06/03/2026 on Nasdaq, according to MarketScreener data as of 06/03/2026.

In Germany, the shares are also available for trading on platforms such as Tradegate, giving euro-based investors an additional access point to the U.S. biopharmaceutical group.

The insider transaction follows Gilead's recent clinical milestone in the United States, where the company announced on 06/02/2026 that liver disease candidate Livdelzi (seladelpar) achieved statistically significant composite ALP normalization in the Phase 3 IDEAL trial in primary biliary cholangitis, according to the company's investor relations news overview.

Gilead highlighted that Livdelzi delivered normalization of key liver markers in a subset of patients with primary biliary cholangitis in late-stage testing, underlining management's efforts to broaden the pipeline beyond its long-established HIV franchise.

At the same time, investor materials and industry commentary point out that Gilead is gradually tilting its portfolio from a heavy concentration in HIV toward a more diversified mix in liver disease and oncology, supported by assets such as Livdelzi and cancer therapy Trodelvy, according to analysis on Simply Wall St.

While the insider sale attracted attention, the use of a pre-arranged 10b5-1 plan, as outlined in the Form 4 footnotes, indicates the timing of O'Day's trades was scheduled in advance rather than a discretionary reaction to short-term share price movements.

The combination of an ongoing clinical pipeline update in the United States and an executive share sale disclosure provides fresh inputs for market participants following Gilead Sciences on Nasdaq.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Gilead Sciences
• Sector/industry: Biopharmaceuticals / biotechnology
• Headquarters/country: Foster City, United States
• Core markets: United States, Europe and other international pharmaceutical markets
• Key revenue drivers: HIV therapies such as Biktarvy, hepatitis and liver disease treatments, as well as oncology products including Trodelvy
• Home exchange/listing venue: Nasdaq (GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences focuses on researching, developing and commercializing antiviral, liver disease and oncology therapies, with sales primarily generated from branded prescription medicines across HIV, liver conditions and cancer.

Insider activity and ownership structure

Insider trading disclosures at Gilead Sciences have come back into the spotlight after a Form 4 filing showed that Chairman and CEO Daniel O'Day sold 15,000 shares of common stock on 06/01/2026 in three open-market transactions, each executed at prices close to USD 131 per share, yielding total proceeds of about USD 1.97 million, according to summaries of the SEC filing on StockTitan and GuruFocus.

The filing notes that these sales were carried out pursuant to a Rule 10b5-1 trading plan that O'Day had adopted on 02/25/2026, an automated mechanism designed to allow insiders to diversify or adjust their holdings over time without being seen as trading on undisclosed information; despite the reduction, O'Day remains a significant shareholder, and the broader ownership base continues to be dominated by large institutional investors, as illustrated by holdings such as Natixis Advisors LLC, which reported owning more than 776,000 Gilead shares in a recent filing covering the fourth quarter.

Conclusion

The latest insider trading disclosure for Gilead Sciences, with CEO Daniel O'Day selling 15,000 shares under a pre-arranged 10b5-1 plan, adds another data point for investors monitoring governance and alignment at the U.S.-based biopharmaceutical group.

Set against the backdrop of new Phase 3 data for Livdelzi in primary biliary cholangitis and continuing efforts to expand beyond HIV into liver disease and oncology, the transaction will likely be weighed alongside pipeline progress and core product performance when assessing the stock.

How markets ultimately interpret the combination of clinical milestones, insider activity and institutional ownership trends will depend on subsequent trial readouts, regulatory milestones and the evolution of Gilead Sciences' earnings profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.